Publication:
Prevalence of and Risk Factors for Cognitive Impairment in Patients With Relapsing-Remitting Multiple Sclerosis: Multi-Center, Controlled Trial

dc.authorscopusid6602895100
dc.authorscopusid26649267800
dc.authorscopusid56574066700
dc.authorscopusid23062131200
dc.authorscopusid23037226400
dc.authorscopusid6602398609
dc.authorscopusid57192089168
dc.contributor.authorÖzakbaş, S.
dc.contributor.authorTürkoǧlu, R.
dc.contributor.authorTamam, Y.
dc.contributor.authorTerzi, M.
dc.contributor.authorTaşkapilioǧlu, O.
dc.contributor.authorYucesan, C.
dc.contributor.authorBaser, H.L.
dc.date.accessioned2020-06-21T13:11:13Z
dc.date.available2020-06-21T13:11:13Z
dc.date.issued2018
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Özakbaş] Serkan, Department of Neurology, Dokuz Eylül Üniversitesi, Izmir, Turkey; [Türkoǧlu] Recai, Sultan 2.Abdülhamid Han Eğitim ve Araştirma Hastanesi, Uskudar, Istanbul, Turkey; [Tamam] Yusuf, Dicle Üniversitesi, Diyarbakir, Diyarbakir, Turkey; [Terzi] Murat, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Taşkapilioǧlu] Özlem, Bursa Uludağ Üniversitesi, Bursa, Bursa, Turkey; [Yucesan] Canan, Ankara Üniversitesi, Ankara, Turkey; [Baser] Hatice Limoncu, Department of Neurology, Dokuz Eylül Üniversitesi, Izmir, Turkey; [Gencer] Mehmet, Sultan 2.Abdülhamid Han Eğitim ve Araştirma Hastanesi, Uskudar, Istanbul, Turkey; [Akil] Eşref Ş., Dicle Üniversitesi, Diyarbakir, Diyarbakir, Turkey; [Sen] Sedat, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Turan] Ömer Faruk, Bursa Uludağ Üniversitesi, Bursa, Bursa, Turkey; [Sorgun] Mine Hayriye, Ankara Üniversitesi, Ankara, Turkey; [Yigit] Pinar, Department of Neurology, Dokuz Eylül Üniversitesi, Izmir, Turkey; [Türkeş] Nevin, Bursa Uludağ Üniversitesi, Bursa, Bursa, Turkeyen_US
dc.description.abstractBackground: Cognitive impairment (CI) is a common problem in multiple sclerosis (MS), may occur either in early or late phase of the disease, and impairs quality of life. Objectives: This study aimed to determine the prevalence of CI and related risk factors in relapsing-remitting MS (RRMS) patients in Turkey. Methods: The present cross-sectional, multi-center, and nationally representative study included RRMS patients. Sociodemographic characteristics, cognitive functions and additional outcomes were compared between patients with and without CI. Results: The analyses included 487 RRMS patients. According to the BRB-N battery results, CI prevalence was 53.7%. There was a negative significant correlation of BRB-N subtests with age, disease duration, and EDSS and MSNQ-patient rated scores. On the logistic regression analysis, increased age, living in village/rural area, high income level, and high EDSS score were significant increasing risk factors in the development of CI. Conclusions: This is the first national cognitive data obtained from MS in Turkey, which is a country between Europe and Asia and thus has characteristics of both continents. The similarity of the results of the present study obtained from Turkey to the Western-based data indicates that CI is universal in MS and the main factors affecting CI have not changed. © 2018 Elsevier B.V.en_US
dc.identifier.doi10.1016/j.msard.2018.03.009
dc.identifier.endpage76en_US
dc.identifier.issn2211-0348
dc.identifier.issn2211-0356
dc.identifier.pmid29605801
dc.identifier.scopus2-s2.0-85044620700
dc.identifier.scopusqualityQ2
dc.identifier.startpage70en_US
dc.identifier.urihttps://doi.org/10.1016/j.msard.2018.03.009
dc.identifier.volume22en_US
dc.identifier.wosWOS:000433294800016
dc.identifier.wosqualityQ2
dc.language.isoenen_US
dc.publisherElsevier B.V.en_US
dc.relation.ispartofMultiple Sclerosis and Related Disordersen_US
dc.relation.journalMultiple Sclerosis and Related Disordersen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCognitionen_US
dc.subjectMultiple Sclerosisen_US
dc.subjectPrevalenceen_US
dc.subjectPrognosisen_US
dc.titlePrevalence of and Risk Factors for Cognitive Impairment in Patients With Relapsing-Remitting Multiple Sclerosis: Multi-Center, Controlled Trialen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files